Factor VIII - Shire Pharmaceuticals

Drug Profile

Factor VIII - Shire Pharmaceuticals

Alternative Names: Factor VIII autologous cell therapy - Shire Pharmaceuticals; Factor VIII autologous cell therapy - Transkaryotic Therapies; Factor VIII cell therapy - Shire Pharmaceuticals; Factor VIII cell therapy - Transkaryotic Therapies

Latest Information Update: 02 May 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Haemophilia

Most Recent Events

  • 02 May 2007 No development reported - Phase-I for Haemophilia in USA (SC)
  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
  • 11 Aug 2003 Factor VIII therapy is no longer licensed to Wyeth Pharmaceuticals in Europe; the rights have been reacquired by Transkaryotic and are available for licensing (http://www.tktx.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top